Determined to realize a future in which people with cancer live longer and better than ever before

Syndax

3Q19 EARNINGS PRESENTATION | NOVEMBER 2019

Forward-looking statements disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operations, financial results and the financial condition of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company"), including financial position, strategy and plans, the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, and Syndax's expectations for liquidity and future operations, are forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. New risks emerge from time to time. It is not possible for Syndax's management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax's expectations.

2019: Portfolio prioritization to drive value

Entinostat + exemestane

FDA BTD

Oral, Class I HDAC in HR+ mBC

- Positive OS possible 2Q20
- NDA filing expected 4-6 mos post data
- Efficacy in CDK4,6 treated patients
- Blockbuster potential

Potential near-term FDA approval

SNDX-5613

Oral, Menin inhibitor

- Blocks activity of MLL-fusion proteins
- IND cleared; initial data expected 2020
- Benefit expected in high need AML, ALL
- Blockbuster potential

Targeted therapy provides fast to market opportunity

HR+ mBC – hormone receptor positive metastatic breast cancer; MLL – mixed lineage leukemia; AML – acute myeloid leukemia; ALL – acute lymphoblastic leukemia

Phase 3 E2112: Focused on overall survival

E2112: Exemestane +/- entinostat



Primary endpoint: OS

FDA BTD

National Cancer Institute

ECOG-ACRIN cancer research group
Reshaping the future of patient care

Syndax

E2112 Trial Assumptions

- **80% power** to detect HR = 0.75
- **Minimal** HR detectable = 0.82
  - Equates to a clinically meaningful risk reduction and ~5 mo mOS benefit
- **2Q20**: Final OS analysis anticipated

A positive OS result allows filing for full regulatory approval

Blockbuster potential as 2nd/3rd line agent

Leading treatment options - HR+, HER2- advanced breast cancer

1st line hormone Tx	2nd/3rd/4th line hormone Tx	Chemo-Tx
Anastrozole or letrazole +/- CDK4,6 inhibitor	Anastrazole, Faslodex +/- CDK4,6 inhibitor or Afinitor-exemestane	Capecitabine, gemcitabine, eribulin

34,000 pts

Entinostat-exemestane target population

US commercial launch preparation underway

Source: DataMonitor 2017 Breast cancer: HR+/HER2- Disease Coverage Report; IQUVIA Monthly treatment report (2018)

MLL wildtype and fusion proteins maintain Menin-binding region

- Menin binding motif found at the amino (N)-terminus of MLL protein
- Menin binding motif on MLL1 retained in MLLr leukemias and NPM1 AML



Source: 1. Yokoyama A, Cell. 2005 Oct 21;123(2):207-18

SNDX-5613 is rationally designed to block the interaction between Menin and MLL-1

Crystal structure of Menin inhibitor bound to Menin



9------13

M-A-H-S-C-R-W-R-***F-P-A-R-P***-G-T-T-G-G-G-

- Inhibitors derived through structure-based drug design
- Inhibitors sit in highly conserved MLL-binding pocket on Menin

Binding of Menin to MLL1 leads to upregulation of HOX gene transcription and leukemia in MLLr AML and MLLr ALL



Adopted from: Uckelmann HJ, et al. Presented at ASH Annual Meeting, 2018.

AUGMENT clinical program: testing oral Menin inhibitor, SNDX-5613, in patients with relapse / refractory acute leukemia

Phase 1:
Dose escalation

Enrolling R/R acute leukemias*
Accel. titration into 3+3 design
28 day cycle



Endpoints: Safety, PK, RP2D

Phase 2:
Expansion

- Adult MLL-r ALL
- Adult MLL-r AML
- Adult NPM1 mut AML

Primary endpoint:
CR Rate (CR + CRh^)

* Unselected population; ^ CR = Complete response, CRh = Complete response with partial hematologic recovery; MLL-r – mixed lineage leukemia rearranged; NPM = nucleophosmin

Update on SNDX-6352: pursuing novel indication

High affinity, IgG4 (K_D = 4-8 pM)

- ✓ Chronic graft versus host disease (cGVHD) study ongoing
  - FDA approved broadening enrollment criteria for prior ibrutinib therapy and lowering age restriction
  - Expect phase 1 dose escalation results in 2H20
- ✓ Ascending dose trials:
  - ✓ Identified RP2D in combo with IMFINZI® (durvalumab, AZ)
  - Monotherapy (solid tumors) ongoing



CSF-1R – colony stimulating factor -1 receptor; RP2D recommended Phase 2 dose.
Source : Ordentlich, P. et al SITC 2016.

Proven ability to build the pipeline

3Q16: UCB

SNDX-6352

4Q17: Allergan/Vitae



Menin-MLLr inhibitors

- Established relationships enhance identification and access to quality assets
- Clinical development leadership enables competitive advantage
- Business development continues to be a core strength of our business

3Q 2019 financial highlights and 4Q, full-year 2019 guidance

Ticker	SNDX (NASDAQ)	
As of Sept 30, 2019		
Cash and short-term investments	$72.2 million	
Shares Outstanding*	31.6 million	
2019 4Q and full year Operating Expense Guidance		
	4Q 2019	**2019**
Research and Development	$11 – 12 M	$45 - 46 M
Total Operating Expenses^	$15 – 16 M	$60 – 62 M

** Includes 27.1 million common shares and pre-funded warrants to purchase 4.5 million common shares*

^ Includes $1.5 and $6 million non-cash stock compensation expense for 4Q 2019 and for 2019, respectively

Key upcoming milestones

ENTINOSTAT (Class 1 specific HDAC inhibitor)	4Q19	1Q20	2Q20	2H20
E2112 – Final Overall Survival analysis			●	

SNDX-5613 (Menin inhibitor)	4Q19	1Q20	2Q20	2H20
Results from Phase 1 portion of AUGMENT (in R/R acute leukemias)		▬	▬	▬

SNDX-6352 (anti-CSF-1R mAB)	4Q19	1Q20	2Q20	2H20
Results from Phase 1 chronic GVHD trial				●

Thank you. Questions?

Syndax